Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Cisco Restructures for AI Growth After Record Q3 Revenue 
Anthropic Eyes $300M Stainless Acquisition Amid Enterprise AI Expansion 
U.S. Army Soldier Charged in $400K Insider Betting Scheme on Maduro Capture 
Argentina Court Upholds Cristina Kirchner Asset Seizure in Corruption Case 
Coles “Down Down” Ruling Sparks Fresh Scrutiny of Australian Supermarket Pricing 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Arcadia Mayor Eileen Wang Pleads Guilty in China Foreign Agent Case 
SK Hynix Nears $1 Trillion Market Value Amid South Korea’s AI-Driven Stock Market Surge 
Japan’s Top Banks to Gain Access to Anthropic’s Claude Mythos AI Model 
Dulles Airport Rebuild Plan Could Transform Washington’s Main International Gateway 
Nidec Shares Plunge After Quality Inspection Misconduct Allegations 
OpenAI Finds No Evidence of User Data Breach in TanStack npm Supply-Chain Attack 
Judge Orders Release of Family After Longest ICE Detention Under Trump Administration 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
